Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 79,660 shares of the company’s stock after buying an additional 2,166 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Novo Nordisk A/S were worth $9,485,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. International Assets Investment Management LLC raised its position in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the period. DSM Capital Partners LLC grew its stake in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after buying an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd acquired a new stake in Novo Nordisk A/S in the third quarter worth $98,765,000. Marshall Wace LLP lifted its stake in Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after buying an additional 689,441 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the second quarter valued at $41,646,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $106.15 on Wednesday. The stock’s 50 day moving average price is $114.32 and its 200 day moving average price is $128.49. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The stock has a market cap of $476.35 billion, a price-to-earnings ratio of 34.35, a PEG ratio of 1.35 and a beta of 0.42. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on NVO shares. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.